Please read and agree to the
terms and conditions
of this site.
I agree
Stream
/news
Clear filters and search
Format
photo
Tags
eli lilly and company
health medical pharma
novo nordisk
peptide hormones
peptide therapeutics
semaglutide
us food and drug administration
anti obesity medication
eli lilly
in denmark
in science
ro
tirzepatide
anti diabetic drugs
bruce gil
bryan johnson
compounding
cvs
diabetes
diabetes medication
donald trump
elite pharmaceuticals inc
food and drug administration
geoff cook
glp 1
glp 1 receptor agonists
glp 1s
glucagon like peptide 1
hims hers
insulin
jr
kennedy
mounjaro
nestle
noom
ozempic
pfizer
pfizers
pharmaceutical industry
pharmacy benefit management
What
food
4
×
glp
4
×
loss
u.s
4
×
weight
administration
drug
fda
read
active
drugs
ingredient
makers
news
nordisk’s
novo
ozempic
pharma
thursday
advancing
analyst
approve
believes
bloomberg
brand
ceo
changing
class
commission
competitive
convinced
daily
decision
development
doctor
drink
effect
eli
fda's
federal
Language
unset
Current search:
glp
×
food
×
u.s
×
@qz.com
17 days ago
Off-brand weight-loss drug makers are suing the FDA, again
@qz.com
3 months ago
Nestle's GLP-1 'shot,' the FDA's Zepbound ruling, and Ozempic lures people to the doctor: Pharma news roundup
@qz.com
8 months ago
Pfizer's weight loss pill, FDA rejects Novo's weekly insulin, and FTC says drug middlemen are hiking prices: Pharma news round up
@fastcompany.com
a year ago
Ozempic is not going to slim down your stock portfolio (yet)